On November 23, 2025, a new clinical trial was announced focusing on the comparative effectiveness of Extracorporeal Shockwave Therapy (ESWT) versus conventional physical therapy techniques for Greater Trochanteric Pain Syndrome (GTPS). Sponsored by Kanuni Sultan Suleyman Training and Research Hospital, this study is notable for its emphasis on evaluating advanced medical device interventions, including ESWT, against traditional approaches that leverage methods such as TENS, hot packs, and ultrasound therapies. Regulatory and clinical stakeholders are encouraged to monitor developments closely as this trial progresses. The full study is currently in the ‘not yet recruiting’ stage.
What is Greater Trochanteric Pain Syndrome?
Greater Trochanteric Pain Syndrome (GTPS) is a musculoskeletal condition commonly associated with lateral hip pain and tenderness over the greater trochanter. GTPS is often linked to injuries or overuse affecting the tendons around the hip area. The condition affects mobility and overall quality of life in patients and is increasingly prioritized for research due to growing incidence rates.
What is Extracorporeal Shockwave Therapy and why is it being studied?
Extracorporeal Shockwave Therapy (ESWT) is a non-invasive medical device intervention that utilizes acoustic waves to target damaged or inflamed tissues. The high-energy waves may induce cellular repair processes, reduce pain, and enhance recovery when applied to the affected area. ESWT has gained attention for its demonstrated efficacy in other orthopedic and musculoskeletal conditions, sparking interest in its potential benefits for treating GTPS. Investigating ESWT in a trial environment against traditional therapies is essential to determine its clinical performance, safety, and optimized application scope in real-world settings.
How does ESWT compare to conventional physical therapy techniques?
Conventional physical therapy for GTPS typically includes methods such as:
- TENS: Transcutaneous Electrical Nerve Stimulation (TENS) devices provide low-voltage electrical currents to relieve pain.
- Hot Pack Therapy: Heat application may promote better blood flow and reduce muscle stiffness.
- Ultrasound Therapy: Ultrasound energy stimulates tissue repair and reduces inflammation.
These therapies are widely used but often have variable efficacy depending on the patient population. The clinical trial aims to evaluate whether ESWT offers superior pain reduction, increased mobility, or faster recovery compared to these well-established techniques.
What is the status of the study?
The trial remains in the ‘not yet recruiting’ stage as of the publication date, November 23, 2025. The study is sponsored by Kanuni Sultan Suleyman Training and Research Hospital and stems from a need for well-validated, evidence-based data to guide medical device integration into GTPS treatment protocols. Once active, the study results will likely inform regulatory decisions, clinical recommendations, and future innovation pathways for musculoskeletal interventions.
Frequently Asked Questions
1. What makes ESWT suitable for GTPS?
ESWT’s ability to target localized tissue inflammation and support cellular repair processes makes it a promising therapy for musculoskeletal disorders like GTPS.
2. Why compare ESWT to traditional methods?
Traditional therapies like TENS and ultrasound are long-standing in physical therapy. Comparing ESWT ensures scientific scrutiny of its advantages and limitations.
3. When will recruitment begin?
The exact recruitment timeline has not been announced. Stakeholders should monitor updates from ClinicalTrials.gov for changes in status.
Conclusion
The introduction of this clinical trial highlights the pivotal role of innovative medical devices like ESWT in tackling persistent conditions such as GTPS. As findings emerge, clinical, quality, and regulatory teams will gain valuable insights into improving treatment protocols and advancing musculoskeletal care.
Disclaimer
Information provided in this article is for professional informational purposes only. It does not constitute legal or clinical advice. Stakeholders should consult directly with regulatory agencies or professional advisors regarding specific decisions.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07243327?term=medical+device